Evolus, Inc.

NasdaqGM EOLS

Evolus, Inc. Market Capitalization on January 14, 2025: USD 599.65 M

Evolus, Inc. Market Capitalization is USD 599.65 M on January 14, 2025, a -2.48% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Evolus, Inc. 52-week high Market Capitalization is USD 1.10 B on September 13, 2024, which is 83.45% above the current Market Capitalization.
Evolus, Inc. 52-week low Market Capitalization is USD 599.65 M on January 14, 2025, which is 0.00% below the current Market Capitalization.
Evolus, Inc. average Market Capitalization for the last 52 weeks is USD 815.05 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGM: EOLS

Evolus, Inc.

CEO	Mr. David Moatazedi
IPO Date	Feb. 8, 2018
Location	United States
Headquarters	520 Newport Center Drive
Employees	322
Sector	Consumer Discretionary
Industries Cosmetics Biotechnology Pharmaceuticals

Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Key trends

Past 5 years